Estrogen News and Research

Latest Estrogen News and Research

Soy may effectively reduce menopausal hot flashes

In the most comprehensive study to date to examine the effects of soy on menopause, researchers have found that two daily servings of soy can reduce the frequency and severity of hot flashes by up to 26 percent, compared to a placebo.

5 Apr 2012

New cell and animal model of IBC

Inflammatory breast cancer (IBC) is a very aggressive, often misunderstood type of cancer that is diagnosed more frequently in younger women compared with other types of breast cancer. The five-year survival rate is between 25 and 50 percent-significantly lower than the survival rate for other types of breast cancer. The reason for the poor prognosis is that IBC usually grows rapidly and often spreads quickly to other parts of the body, including the brain, bone and lymph nodes.

5 Apr 2012

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

UCB and Amgen announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

4 Apr 2012

CYP1B1 protein may be a potential target for intervention in head and neck cancer

Squamous cell carcinoma of the head and neck-which typically arises from thin, flat cells that line moist surfaces inside the mouth, nose and throat-is the sixth most common type of cancer worldwide, and it has a relatively low five-year survival rate and a high recurrence rate.

2 Apr 2012

TGen to present TNBC study at AACR 2012 annual meeting

Because cases of Triple-Negative Breast Cancer (TNBC) are so genetically different, whole-genome sequencing is needed to detect the subtle molecular differences that might point to specific treatments for individual patients.

2 Apr 2012

Scientists use DNA sequencing to identify 'driver' mutations in cancer

Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor - considered key to personalizing cancer treatment - but to map the genetic evolution of disease and monitor response to treatment.

2 Apr 2012

STAT-1 and PLSCR-1 proteins could play a crucial role in breast cancer

At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells.

2 Apr 2012

Aberrations in translation regulators linked with hormone receptor-positive breast cancer survival

Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported at the AACR Annual Meeting 2012.

2 Apr 2012

FDA won’t ban bisphenol A from food packaging

In a long drawn decision the U.S. government announced Friday that it will not ban bisphenol A, an industrial chemical believed to disrupt the reproductive and nervous systems, from food and drink packaging.

1 Apr 2012

Hormones use and breast cancer risk

...

1 Apr 2012

IMS supports new guidance on glucocorticoid use

The International Osteoporosis Foundation, along with the European Society for Calcified Tissue, launched new guidance on glucocorticoid use at the European Congress on Osteoporosis and Osteoarthritis (which took place in Bordeaux from March 21 - 24, 2012). Given the special relevance to postmenopausal women, the International Menopause Society (IMS) is supporting the publication of the guidance.

31 Mar 2012

Bionovo 2011 total revenues decrease to $0.3 million

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced financial results for the year ended December 31, 2011.

31 Mar 2012

DSMB recommends Bionovo to continue Menerba Phase 3 trial for hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that the Company's independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial of Menerba (MF101) could continue as designed after an initial review of its clinical safety and tolerability data.

29 Mar 2012

Protein's location in a cell affects impact on disease

If the fight against breast cancer were a criminal investigation, then the proteins survivin, HDAC6, CBP, and CRM1 would be among the shadier figures. In that vein, a study to be published in the March 30 Journal of Biological Chemistry is the police report that reveals a key moment for keeping cancer cells alive: survivin's jailbreak from the nucleus, aided and abetted by the other proteins.

29 Mar 2012

Transplanted ovaries can delay menopause and allow for a successful pregnancy

Researchers may have found a way to end menopause after proving that transplanted ovaries remain effective for at least seven years. Of the three women, one has had three children since her transplant, a second has had two and the third is expecting her third child. Medical experts believe the three could be the pioneers for a treatment that would allow women to delay motherhood.

26 Mar 2012

Testosterone receptor may be a potential target for triple negative breast cancer

Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. Preliminary results of a Mayo Clinic - TGen collaborative study shows the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).

26 Mar 2012

Testosterone may play a role in treatment of triple negative breast cancer

23 Mar 2012

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

23 Mar 2012

Treatment with aromatase inhibitors enables some women to have lumpectomy

Preoperative treatment with aromatase inhibitors increases the likelihood that postmenopausal women with estrogen receptor-positive breast cancer will be able to have breast-conserving surgery rather than a mastectomy, according to the results of a national clinical trial presented today at the Society of Surgical Oncology annual meeting in Orlando, Fla.

23 Mar 2012

Only few OB-GYNs routinely inquire about patients' sexual issues

How often does your doctor ask about your sexual life? Unfortunately, the answer may be: not often enough. Leaving the subject off the check-up checklist could mean missing an important link to overall wellness.

23 Mar 2012